Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

After bruising rejection, bluebird and Bristol Myers Squibb land ide-cel priority review. But will it matter for the CVR?

5 years ago

Rocked by customs investigation, Legend's CFO takes over as CEO Frank Zhang placed under house arrest

5 years ago

#ESMO20: Autolus provides glimpse of next-generation CAR-T program, showing early positive safety data

5 years ago

A longtime CytomX exec re-emerges at Synthekine, an $82M Stanford spinout

5 years ago

Sarepta faces another gene therapy hiccup as Regenxbio sues over Jim Wilson's patent

5 years ago

Moderna picks up a $75M cash windfall as longtime collaborator Vertex signs up for a gene editing assault on cystic fibrosis

5 years ago

Versant teams up with Stanford gene editing experts on a $45M next-gen play — marrying CRISPR and AAV to fix sickle cell

5 years ago

Takeda opens cell therapy manufacturing facility — tucked right in its Boston R&D hub

5 years ago

Scoop: Gilead’s CAR-T player Kite waves goodbye to research chief Peter Emtage as another top exec hits the exit

5 years ago

MiNA Therapeutics bags nearly $30M Series A to push activating mRNA tech through the clinic

5 years ago

Closely-watched international CRISPR ethics panel leaves door ajar for germline editing — one day

5 years ago

Researchers at City of Hope combine oncolytic virus with a CAR-T to eradicate solid tumors in mice

5 years ago

Researchers teamed up to develop a 'three in one' HIV treatment — and the NIH is throwing in $14.6M

5 years ago

Crossover round? Check. Top team? Check. Taysha sails to an IPO with $100M initial ask

5 years ago

Game change: A frontrunner in the cell therapy 2.0 field offers a first look at their lead therapy. And it’s a doozy

5 years ago

Sold for pennies, Unum gets one last shot at redemption

5 years ago

Synthego adds $100M from RA, Wellington, 8VC in pursuit of 'virtualizing biology'

5 years ago

Derailed gene therapy study reports 3rd death as safety and durability issues cloud a booming field

5 years ago

Daniel O’Day’s I/O dance continues, as Gilead and Tango expand deal up to $6B

5 years ago

Taysha buys clinic-ready gene therapy from Abeona, bringing Steven Gray's portfolio back in one place

5 years ago

Teamed up with Lyell, Juno/WuXi joint venture files IPO betting on China's CAR-T future

5 years ago

BioMarin CSO disses rivals for the hemophilia A gene therapy crown: Way behind, facing big recruitment challenges and at best a .6 on the gen-one scale

5 years ago

Novartis’ CAR-T partner in China wraps $383M take-private deal engineered by CEO

5 years ago

CF Foundation, Longwood team on new incubator for companies with cutting-edge CF treatments

5 years ago

First page Previous page 44 45 464748 49 50 Next page Last page